- Joined
- Dec 3, 2017
- Messages
- 26,290
- Reaction score
- 16,771
- Gender
- Male
- Political Leaning
- Progressive
Partnership to test pancreas drug in COVID-19
This trial, funded by the government-backed charity LifeArc, is a partnership between the CDD, privately-held biotech company Latus Therapeutics and the University of Edinburgh.
It will investigate whether a drug called camostat, which has been shown in the lab to prevent COVID-19 from entering human cells, could help control symptoms of the virus and prevent people that are infected needing to go to hospital.
Camostat is already licensed in Japan and South Korea to treat pancreatic disease, so if successful it could be quickly manufactured and used to treat people with COVID-19.
Almost half of UK COVID-19 patients requiring critical care have died in hospital so far. Currently, there is a limited number of treatment options available for people affected by COVID-19, with one option at least offered by the recently approved antiviral drug remdesivir, from Gilead Sciences
====================================================================
A host enzyme is required to trigger the injection of the spike or S protein of the virus into cells. Camostat blocks that enzyme. It is already in clinical trials in Europe. It is already approved in Japan & Korea for treating pancreatitis.
This trial, funded by the government-backed charity LifeArc, is a partnership between the CDD, privately-held biotech company Latus Therapeutics and the University of Edinburgh.
It will investigate whether a drug called camostat, which has been shown in the lab to prevent COVID-19 from entering human cells, could help control symptoms of the virus and prevent people that are infected needing to go to hospital.
Camostat is already licensed in Japan and South Korea to treat pancreatic disease, so if successful it could be quickly manufactured and used to treat people with COVID-19.
Almost half of UK COVID-19 patients requiring critical care have died in hospital so far. Currently, there is a limited number of treatment options available for people affected by COVID-19, with one option at least offered by the recently approved antiviral drug remdesivir, from Gilead Sciences
====================================================================
A host enzyme is required to trigger the injection of the spike or S protein of the virus into cells. Camostat blocks that enzyme. It is already in clinical trials in Europe. It is already approved in Japan & Korea for treating pancreatitis.
Last edited: